PG 27
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Pharmagenesis
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
- Discontinued Autoimmune disorders; Graft-versus-host disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 20 Oct 2017 PG 27 is available for licensing in (excluding Taiwan, China) as of 20 Oct 2017. http://www.pharmagenesis.net/Pipeline.htm
- 19 Oct 2015 Preclinical development is ongoing in USA